The Board of Directors of Mahi Drugs Private Limited, a material subsidiary of Haleos Labs Limited (formerly known as SMS Lifesciences India Limited), convened a meeting on August 5, 2026, and approved two significant corporate actions — the appointment of a new Nominee Director and the appointment of Cost Auditors for the financial year 2026-27. The disclosures were made pursuant to Regulation 30(9) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Appointment of Nominee Director

Mr. Vincent P. Asaro has been appointed as the Nominee Director of Mahi Drugs Private Limited, as nominated by ChemWerth Inc., with effect from August 5, 2026. He replaces Mr. M. Madhu Rao, who ceased to be the Nominee Director of the subsidiary company with effect from the same date. The key details of the appointment are as follows:

Profile of Mr. Vincent P. Asaro

Mr. Asaro is a Certified Public Accountant (CPA) and holds an MBA in Finance from the University of Connecticut and a Bachelor of Science in Accounting from Providence College. He has also completed executive education at Harvard Business School. He is the President of ChemWerth Inc., a leading global developer and supplier of Active Pharmaceutical Ingredients (APIs) to regulated pharmaceutical markets worldwide.

With over 35 years of experience in finance, corporate strategy, business development, and pharmaceutical operations, Mr. Asaro has played a pivotal role in driving ChemWerth's growth and strengthening its global presence. Prior to his role as President, he served as the Chief Financial Officer of ChemWerth Inc. since 2009, where he led the company's financial strategy, operational excellence, and business expansion initiatives. Earlier in his career, he held finance and leadership positions with Deloitte & Touche and Bayer, gaining extensive expertise in accounting, auditing, internal controls, and corporate finance. He also serves on the Board of Directors of Bedoukian Research, Inc.

Appointment of Cost Auditors for FY 2026-27

The Board also approved the appointment of Annapragada & Co. as Cost Auditors of Mahi Drugs Private Limited for the financial year 2026-27, pursuant to the provisions of Section 148 of the Companies Act, 2013, read with Rule 14 and other applicable rules of the Companies (Audit and Auditors) Rules, 2014. The remuneration shall be subject to ratification by shareholders at the next Annual General Meeting.

Annapragada & Co. is a firm of Cost Accountants with experience in Cost Audits, Finance, Forecasting, and process improvement. The firm has demonstrated expertise in developing and implementing cost accounting systems, analysing cost trends, and providing accounting support to various operating groups and manufacturing plants, along with knowledge of relevant government regulations, internal controls, cost accounting methods, and cost modelling tools.

Disclosure and Compliance

The above developments were communicated to BSE Limited and the National Stock Exchange of India Limited by Trupti Ranjan Mohanty, Company Secretary of Haleos Labs Limited, in accordance with applicable listing regulations. The information is also available on the company's website at www.haleoslabs.com .

Haleos Labs Limited has approved the reappointment of Dr. Mannam Malakondaiah and Dr. Srinivas Samavedam as independent directors for a second consecutive term of five years. The Board of Directors made the decision at its meeting held on August 5, 2026, based on the recommendation of the Nomination and Remuneration Committee. The new terms commence on November 13, 2026, subject to the approval of shareholders. This move ensures continuity in board oversight, with both directors bringing decades of specialized expertise in public administration and critical care medicine to the company’s governance structure.

The reappointment was disclosed to BSE Limited and National Stock Exchange of India Limited in compliance with Regulation 30 (6) read with sub-para 7 of para "A" of part "A" of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The filing confirms that neither director is debarred from holding office by virtue of any SEBI order or other authorities, as per circulars NSE/CML/2018/02 and LIST/COMP/14/2018-19 dated June 20, 2018.

Director Profiles and Tenure

Both directors are completing their first tenure, which ends on November 12, 2026. Their reappointment marks the start of their maximum allowable second consecutive term under regulatory guidelines.

Dr. Mannam Malakondaiah, a distinguished 1985 Batch Indian Police Service officer, retired as Director General of Police, Andhra Pradesh, on June 30, 2018. He previously served as Vice-Chairman and Managing Director of APSRTC and has held senior roles in APTRANSCO and CISF. Currently an Honorary Advisor to Vignan University, he brings extensive experience in public administration and law enforcement to the board.

Dr. Srinivas Samavedam is a leading Critical Care Medicine specialist with over 26 years of experience. He serves as Consultant & Head – Critical Care at Sindhu Hospitals, Hyderabad, and is credited with introducing ECMO services in the city. His academic credentials include an MD and DNB in Internal Medicine, FNB in Critical Care Medicine, and a European Diploma in Intensive Care.

Committee Memberships

The filing details the committee compositions for both directors, highlighting their governance responsibilities within the company.

Dr. Mannam Malakondaiah:

• Audit Committee: Member
• Nomination and Remuneration Committee: Chairman
• Corporate Social Responsibility Committee: Member

Dr. Srinivas Samavedam:

• Nomination and Remuneration Committee: Member
• Corporate Social Responsibility Committee: Member

No relationship exists between the two directors, as confirmed in the disclosure. Detailed profiles are available on the company website.